BENDITA BEnznidazole New Doses Improved Treatment and Associations
Status:
Unknown status
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
Recent scientific advances have provided further impetus to develop new therapeutic
approaches for Chagas Disease (CD) using different doses and duration of BZN, as well as
combinations directed at multiple therapeutic targets to improve treatment response and
tolerability and reduce the potential for development of resistance.
This project focuses on the proof-of-concept evaluation of improved treatment regimens of
BZN, with the assessment of new BZN-sparing regimens in monotherapy and in combination with
E1224.